{"filing":{"accession_number":"0001104659-26-066572","cik":"0001974640","ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"tm2615568d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/tm2615568d1_8k.htm"},"events":[{"id":8660,"run_id":7604,"accession_number":"0001104659-26-066572","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Apogee disclosed positive Phase 2 clinical trial results for zumilokibart (APG777) in atopic dermatitis, with the APEX Part B 16-week induction data meeting its primary endpoint (EASI-75) and key secondary endpoints across multiple dose cohorts with statistical significance (p\u003c0.001) and a favorable safety profile, supporting advancement to Phase 3 development.","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1793,"accession_number":"0001104659-26-066572","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Apogee disclosed positive Phase 2 clinical trial results for zumilokibart (APG777) in atopic dermatitis via press release and data presentation under Item 7.01 (Regulation FD Disclosure). While clinical trial results are material to biotech investors and would affect the total mix of information available, this disclosure does not fit neatly into the predefined taxonomy categories (earnings_release, exec_departure, ma_activity, etc.). The event is material because positive Phase 2 data typically impacts stock valuation and investor sentiment for clinical-stage biopharmaceutical companies, but it is best classified as other_material rather than forcing it into an inapplicable category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:28.021260+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1794,"accession_number":"0001104659-26-066572","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 2 clinical trial results for zumilokibart (APEX Part B 16-week induction data) meeting its primary endpoint (EASI-75) and key secondary endpoints across multiple dose cohorts with statistical significance (p\u003c0.001), along with a favorable safety profile. While this is a material clinical development for a biopharmaceutical company's lead candidate, it does not fit neatly into the earnings_release category (no financial results) nor any other specific event type. The announcement of clinical trial results and advancement to Phase 3 is material to investors assessing the registrant's pipeline progress and commercial prospects, but lacks a dedicated taxonomy category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:28.021260+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1793,"accession_number":"0001104659-26-066572","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Apogee disclosed positive Phase 2 clinical trial results for zumilokibart (APG777) in atopic dermatitis via press release and data presentation under Item 7.01 (Regulation FD Disclosure). While clinical trial results are material to biotech investors and would affect the total mix of information available, this disclosure does not fit neatly into the predefined taxonomy categories (earnings_release, exec_departure, ma_activity, etc.). The event is material because positive Phase 2 data typically impacts stock valuation and investor sentiment for clinical-stage biopharmaceutical companies, but it is best classified as other_material rather than forcing it into an inapplicable category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:28.021260+00:00","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-05-27"},{"id":1794,"accession_number":"0001104659-26-066572","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 2 clinical trial results for zumilokibart (APEX Part B 16-week induction data) meeting its primary endpoint (EASI-75) and key secondary endpoints across multiple dose cohorts with statistical significance (p\u003c0.001), along with a favorable safety profile. While this is a material clinical development for a biopharmaceutical company's lead candidate, it does not fit neatly into the earnings_release category (no financial results) nor any other specific event type. The announcement of clinical trial results and advancement to Phase 3 is material to investors assessing the registrant's pipeline progress and commercial prospects, but lacks a dedicated taxonomy category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:28.021260+00:00","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-05-27"}]}